HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IART
Integra LifeSciences Holdings Corporation
IART's fundamentals are strong, but it looks expensive: trading at 90x earnings, more than twice its usual 34x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IART Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
IART's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IART PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.2x | $14.35 | — |
| Cheap | 26x | $4.14 | -71% |
| Fair | 34x | $5.42 | -62% |
| Expensive | 84x | $13.36 | -6.9% |
| Current | 90x | $14.35 | — |
Historical ranges are pointers, not guarantees.
IART's PE is in its expensive range at 90x. On analysts' estimates for next year's earnings, today's price would be 6.2x, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IART Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect IART's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IART Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +1357% |
| Q3 2026 | $0.16 | +$6.62 |
| Q2 2026 | -$0.10 | +$6.43 |
| Q1 2026 | -$6.47 | -$6.09 |
| Q4 2025 | -$6.74 | -$6.65 |
| Q3 2025 | -$6.46 | -$6.38 |
| Q2 2025 | -$6.53 | -2277% |
| Q1 2025 | -$0.38 | -175% |
| Q4 2024 | -$0.09 | -111% |
IART has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IART on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IART Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $411.2M | +2.3% |
| Q2 2026 | $418.8M | +0.8% |
| Q1 2026 | $391.9M | +2.4% |
| Q4 2025 | $434.9M | -1.7% |
| Q3 2025 | $402.1M | +5.6% |
| Q2 2025 | $415.6M | -0.6% |
| Q1 2025 | $382.7M | +3.7% |
| Q4 2024 | $442.6M | +11% |
IART's revenue grew through 2021 and has held roughly level since: $411M last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.6% | +1.7 points |
| Q2 2026 | 4.6% | +128 points |
| Q1 2026 | 2.9% | +7 points |
| Q4 2025 | 5.3% | -2.8 points |
| Q3 2025 | 2.9% | +5.1 points |
| Q2 2025 | -123% | -123 points |
| Q1 2025 | -4% | -5.1 points |
| Q4 2024 | 8.1% | -1 points |
IART has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IART on cash flow, with more consistent year-over-year improvement.
IART Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $85.7M | +233% |
| Q2 2026 | $10.5M | +$21.7M |
| Q1 2026 | -$5M | +$35.1M |
| Q4 2025 | -$5.4M | -126% |
| Q3 2025 | $25.8M | +$32.9M |
| Q2 2025 | -$11.2M | -205% |
| Q1 2025 | -$40.2M | -13907% |
| Q4 2024 | $21.1M | -38% |
IART's free cash flow has turned positive again: $86M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IART on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IART Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +409K shares |
| 1 year | +2.4% | +1.8M shares |
| 3 years | -1.5% | -1.2M shares |
| 5 years | -8% | -6.9M shares |
| Available history | -9.2% | -7.9M shares |
IART has 79M diluted shares, up 2.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $2.5M |
| Q3 2024 | — |
| Q2 2024 | $50M |
| Q1 2024 | — |
| Q4 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IART Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 3.0x | Elevated |
| Q1 2020 | 2.6x | Moderate |
| Q4 2019 | 3.3x | Elevated |
IART's net debt is about 3.0 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IART Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 26.2 | Neutral |
IART's weekly RSI is 49 (neutral) and its Stochastic is 26 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IART PE vs Healthcare Sector
| Metric | IART | Sector median | Relative |
|---|---|---|---|
| PE | 90x | 26x | 247% above |
| PE % | 89 | 29 | 60 pts above |
IART is trading at 90x earnings, a 247% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IART Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.5 | 6.5% above |
| 20 week MA | $15.9 | 9.5% below |
| 50 week MA | $13.9 | 3.2% above |
| 100 week MA | $15.3 | 6.1% below |
| 200 week MA | $26.4 | 46% below |
IART has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IART Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.7 | $66.4 | +13% |
| 2021 | $66.4 | $68.3 | +2.8% |
| 2022 | $68.3 | $56.3 | -18% |
| 2023 | $56.3 | $43.6 | -23% |
| 2024 | $43.6 | $22.3 | -49% |
| 2025 | $22.3 | $12.6 | -43% |
| 2026 YTD | $12.6 | $14.4 | +14% |
IART has the edge over HIMS on returns for 2026, with the stronger performance.